An object of the present invention is to provide a method for preventing precipitation by storing an injection solution for boron neutron capture therapy. The present invention provides a method for preventing precipitation of an injection solution for boron neutron capture therapy, the injection solution containing p-boronophenylalanine or a pharmaceutically acceptable salt thereof; a sugar alcohol; and a pH adjusting agent, having a pH of 6.5 to 8.0 and an osmotic pressure ratio of 1.0 to 1.8, and being to be administered by intravenous drip injection.

The present invention provides a novel macromolecular drug, more specifically, a complex comprising a styrene-maleic acid copolymer (SMA) and a boric acid compound, wherein the SMA is bound to the boric acid compound directly or through a linker.

A neutron capture therapy system and a target for a particle beam generating device, which may improve the heat dissipation performance of the target, reduce blistering and extend the service life of the target. The neutron capture therapy system includes a neutron generating device and a beam shaping assembly. The neutron generating device includes an accelerator and a target, and a charg\ed particle beam generated by acceleration of the accelerator interacts with the target to generate a neutron beam. The target includes an acting layer, a backing layer and a heat dissipating structure, the acting layer interacts with the charged particle beam to generate the neutron beam, the backing layer supports the action layer, and the heat dissipating structure includes a tubular member composed of tubes arranged side by side.

Biodegradable Periodic Mesoporous Organosilica (BPMO) nanomaterials and methods of making BPMOs loaded with Neutron Capture Agents are disclosed herein. Consequently, the BPMOs loaded with Neutron Capture Agents provide a method of treating cancer, immunological disorders and other disease by utilizing a Neutron Capture Therapy modality.

Medical technologies for the creation of target agents for boron-neutron capture therapy of oncological diseases. In a first method variant for preparing a composition for boron neutron capture therapy of malignant tumors containing boron nanoparticles less than 100 nm includes: elemental boron powder being placed in water and treated for 0.5 to 800 minutes with ultrasound with vibration intensity from 1, 0 to 1000.0 W/cm.sup.3 and the output power greater than 100.0 W. In a second method variant, elemental boron powder is placed in water and treated for 30 to 300 minutes with ultrasound with a same vibration intensity and output power, then the upper part of the composition is taken in a volume less than 50.0 vol. % of total composition volume and treated with ultrasound with vibration intensity from 1.0 to 1000.0 W/cm.sup.3 and output power greater than 100.0 W for 250-300 minutes.

Systems and methods including a material that emits high energy beta particles to destroy cancer cells contained in cancerous tumor or tissue. Electronic neutron generators produce neutrons with energies that have a high probability to interact with the material yttrium-89 to produce yttrium-90. Yttrium-90 emits beta radiation with a maximum energy of about 2.25 MeV and a half-life of about 64 hours, which decays to stable zirconium. Stable yttrium-89 can be directly placed in or around cancerous tissue and irradiated with neutrons in the 0.1-15 KeV energy range to produce significant amounts of yttrium-90. The beta radiation emitted by yttrium-90 will primarily destroy the more radiation sensitive cancer cells within the range of the beta particles. The resulting zirconium isotope is not radioactive such that no further radiation is released. A low probability gamma is also created that will assist in cancer cell destruction.

Disclosed herein are novel carborane hydroxamic acid matrix metalloproteinase (“MMP”) inhibitors and agents bearing borane-containing moieties and methods for their use in treating or preventing a disease, such as cancer and rheumatoid arthritis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salt thereof: Formula (I) wherein the substituents are as described.

##STR00001##

Compounds containing TRPV6-binding peptides and their use in the detection and diagnosis of cancer are described. Also described are methods for detecting and staging cancer that use the compounds of the invention. Compounds containing TRPV6-binding peptides are useful for the delivery of diagnostic and therapeutic agents to cells or tumors that express TRPV6.

A method comprises providing a plurality of nanostructures comprising a base material. The plurality of nanostructures are exposed to a first material at a first deposition temperature. The plurality of nanoparticles are exposed to a second material at a second deposition temperature, and exposed to a Boron-10 (.sup.10B) containing material at a third deposition temperature so as to form a .sup.10B-metal oxide based composite nanostructure.

The present invention provides a radioactive labeling method for neuropeptide Y (NPY) compound and a mammalian diagnostic radioactive targeting medicine with NPY peptide being modified at position 27.sup.th to 36.sup.th, and after binding with the chelating agent and labeling the radiation nucleus .sup.66Ga.sup.67Ga.sup.68Ga.sup.177Lu or .sup.111In to provide a radioactive targeting medicine for multi-type breast cancer diagnosis and treatment.